Page 55 - JCTR-11-2

Journal of Clinical and
Translational Research CMV secular trends and race

CMV D+/R− while experiencing significantly higher Consent for publication
normalized rates of CMV infection, late CMV infection,
acute rejection, and death-censored graft loss. Notably, these This is a retrospective study utilizing data available in
risks among AAs have shown no significant improvement the MUSC data system. As all data were de-identified and
over this 10-year study period. Additional research analyzed anonymously, patient consent was not required
should focus on the underlying factors contributing to the for publication in accordance with institutional and ethical
guidelines.
elevated incidence of CMV infection among AAs. This
would facilitate the development of targeted interventions Availability of data
to alleviate this disparity. Immunosenescence, which has
documented correlations with CMV, is one phenomenon Data are available from the corresponding author upon
to consider in further research. In addition, studying reasonable request.
genetic polymorphisms could provide additional insights References
into racial disparities in transplant outcomes, potentially
informing strategies to mitigate these disparities. 1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J
Med. 1994;331(6):365-376.
Acknowledgments doi: 10.1056/NEJM199408113310606
None. 2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of
Funding mortality in all patients on dialysis, patients on dialysis
awaiting transplantation, and recipients of a first cadaveric
Research presented in this manuscript was conducted transplant. N Engl J Med. 1999;341(23):1725-1730.
through the support of a grant provided by Merck doi: 10.1056/NEJM199912023412303
Pharmaceuticals.
3. Szumilas K, Wilk A, Wiśniewski P, et al. Current status
Conflict of interest regarding immunosuppressive treatment in patients after
renal transplantation. Int J Mol Sci. 2023;24(12):10301.
David J Taber reports financial support was provided doi: 10.3390/ijms241210301
by Merck & Co Inc. David J Taber reports a relationship
with Veloxis Pharmaceuticals Inc., that includes board 4. Agrawal A, Ison MG, Danziger-Isakov L. Long-term
membership and funding grants. David J Taber reports infectious complications of kidney transplantation. Clin J
Am Soc Nephrol. 2022;17(2):286-295.
a relationship with CareDx Inc., that includes board
membership and funding grants. If there are other authors, doi: 10.2215/CJN.15971020
they declare that they have no known competing financial 5. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical
interests or personal relationships that could have appeared practice guideline for the care of kidney transplant recipients:
to influence the work reported in this paper. A summary. Kidney Int. 2010;77(4):299-311.

Author contributions 6. Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
Cytomegalovirus serostatus pairing and deceased donor
Conceptualization: All authors kidney transplant outcomes in adult recipients with antiviral
Investigation: All authors prophylaxis. Transplantation. 2010;90(10):1091-1098.
Methodology: David J. Taber doi: 10.1097/TP.0b013e3181f7c053
Visualization: David J. Taber 7. Patzer RE, McClellan WM. Influence of race, ethnicity and
Writing – original draft: All authors socioeconomic status on kidney disease. Nat Rev Nephrol.
Writing – review & editing: All authors
2012;8(9):533-541.
Ethics approval and consent to participate doi: 10.1038/nrneph.2012.117
The study conforms to the ethical guidelines of the 8. Ciancio G, Burke GW, Suzart K, et al. The use of daclizumab,
1975 Declaration of Helsinki, as reflected in the prior tacrolimus and mycophenolate mofetil in african-american
approval by the institution’s human research committee. and Hispanic first renal transplant recipients. Am J
Transplant. 2003;3(8):1010-1016.
This study was approved by the Medical University of
South Carolina (MUSC) Institutional Review Board doi: 10.1034/j.1600-6143.2003.00181.x
(IRB) under protocol number Pro00118675. All research 9. Neylan JF. Racial differences in renal transplantation after
procedures were conducted in accordance with MUSC immunosuppression with tacrolimus versus cyclosporine.
ethical committee guidelines. FK506 Kidney Transplant Study Group. Transplantation.

Volume 11 Issue 2 (2025) 49 doi: 10.36922/jctr.24.00067